You are here

Home » Content

Correlation of Osteocalcin Level with Blood Glucose Concentration and Insulin Level in Type II Diabetic Sudanese Patients

Journal Name:

  • International Journal of Medical Research & Health Sciences

Publication Year:

  • 2017

Key Words:

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
Osteocalcin, a bone-derived protein, has recently been reported to affect energy metabolism, this study aimed to evaluate the effects of osteocalcin level on blood glucose concentration and insulin level in type II diabetic Sudanese patients. In this cross-sectional study, one hundred fifteen type II diabetic patients were enrolled in the study (34 males and 81 females) with ages ranging between 18 and 90 years. Total osteocalcin, undercarboxylated osteocalcin, and insulin were measured using ELISA technique. Fasting blood glucose and lipid profile were measured by a spectrophotometer. Mean serum osteocalcin concentration in diabetic patients was significantly lower than those in control subjects (p ≤ 0.001). Undercarboxylated osteocalcin in diabetic patients was significantly lower than in control subjects (p ≤ 0.001). Fasting insulin was significantly higher in diabetic subjects compared to control subjects (p ≤ 0.001). Osteocalcin was negatively correlated with insulin and FBS (r = −0.530; p ≤ 0.001), (r = −0.373; p ≤ 0.001) respectively. Undercarboxylated was negatively correlated with insulin and FBS (r = −0.634; p ≤ 0.001), (r = −0.297; p ≤ 0.001) respectively. Total osteocalcin and undercarboxylated osteocalcin levels of diabetic patients were lower than those of the healthy control subjects. Fasting serum insulin was higher in patients compared to control subjects. Total osteocalcin and undercarboxylated osteocalcin were negatively correlated with Fasting serum insulin and FBS.
Bookmark/Search this post with
FULL TEXT (PDF): 
PDF icon arastirmax-correlation-osteocalcin-level-blood-glucose-concentration-and-insulin-level-type-ii-diabetic-sudanese-patients.pdf
  • 10
87
92
  • English

REFERENCES

References: 

[1] Babikr, Walid G., et al. “Impact of body mass index on hypomagnesemia and hypocalcemia in type 2 diabetic
patients.” Biomedical and Pharmacology Journal Vol. 9, No. 3, 2016, pp. 933-40.
Ogail Yousif Dawod, et al. Int J Med Res Health Sci 2017, 6(10): 87-92
91
[2] World Health Organization, “Diabetes, Fact Sheet. July 2017, http://www.who.int/mediacentre/factsheets/fs312/en/.
[3] Leong, Aaron, et al. “Systematic review and meta-analysis of validation studies on a diabetes case definition from
health administrative records.” PLoS One Vol. 8, No. 10, 2013, p. e75256.
[4] Hassan, Dalin A., et al. “Lipid profile and glycated hemoglobin (HbA1c) in diabetic Sudanese patients.” International
Journal of Science and Research Vol. 4, No. 2, 2015, pp. 1813-16.
[5] Lee, Na Kyung, et al. “Endocrine regulation of energy metabolism by the skeleton.” Cell Vol. 130, No. 3, 2007,
pp. 456-69.
[6] Lombardi, Giovanni, et al. “A four-season molecule: osteocalcin. Updates in its physiological roles.” Endocrine
Vol. 48, No. 2, 2015, pp. 394-404.
[7] O’Connor, Eibhlís M., and Edel Durack. “Osteocalcin: The extra-skeletal role of a vitamin K-dependent protein
in glucose metabolism.” Journal of Nutrition & Intermediary Metabolism Vol. 7, 2017, pp. 8-13.
[8] Murshed, Monzur, et al. “Extracellular matrix mineralization is regulated locally; different roles of two glacontaining
proteins.” The Journal of Cell Biology Vol. 165, No. 5, 2004, pp. 625-30.
[9] Ferron, Mathieu, et al. “Osteocalcin differentially regulates β cell and adipocyte gene expression and affects the
development of metabolic diseases in wild-type mice.” Proceedings of the National Academy of Sciences Vol.
105, No. 13, 2008, pp. 5266-70.
[10] Fernández-Real, Jose Manuel, et al. “The relationship of serum osteocalcin concentration to insulin secretion,
sensitivity, and disposal with hypocaloric diet and resistance training.” The Journal of Clinical Endocrinology &
Metabolism Vol. 94, No. 1, 2009, pp. 237-45.
[11] Pittas, Anastassios G., et al. “Association between serum osteocalcin and markers of metabolic phenotype.” The
Journal of Clinical Endocrinology & Metabolism Vol. 94, No. 3, 2009, pp. 827-32.
[12] Kanazawa, Ippei, et al. “Serum osteocalcin level is associated with glucose metabolism and atherosclerosis
parameters in type 2 diabetes mellitus.” The Journal of Clinical Endocrinology & Metabolism Vol. 94, No. 1,
2009, pp. 45-49.
[13] Kindblom, Jenny M., et al. “Plasma osteocalcin is inversely related to fat mass and plasma glucose in elderly
Swedish men.” Journal of Bone and Mineral Research Vol. 24, No. 5, 2009, pp. 785-91.
[14] Prats-Puig, Anna, et al. “Carboxylation of osteocalcin affects its association with metabolic parameters in healthy
children.” Diabetes Care Vol. 33, No. 3, 2010, pp. 661-63.
[15] Zhou, Mi, et al. “Serum osteocalcin concentrations in relation to glucose and lipid metabolism in Chinese individuals.”
European Journal of Endocrinology Vol. 161, No. 5, 2009, pp. 723-29.
[16] Im, Jee-Aee, et al. “Relationship between osteocalcin and glucose metabolism in postmenopausal women.” Clinica
Chimica Acta Vol. 396, No. 1, 2008, pp. 66-69.
[17] Motyl, Katherine J., Laura R. McCabe, and Ann V. Schwartz. “Bone and glucose metabolism: a two-way
street.” Archives of Biochemistry and Biophysics Vol. 503, No. 1, 2010, pp. 2-10.
[18] Wang, Qingqing, et al. “The relationship between serum osteocalcin concentration and glucose metabolism in
patients with type 2 diabetes mellitus.” International Journal of Endocrinology Vol. 2013, 2013.
[19] Rosato, M. T., S. H. Schneider, and S. A. Shapses. “Bone turnover and insulin-like growth factor I levels increase
after improved glycemic control in noninsulin-dependent diabetes mellitus.” Calcified Tissue International Vol.
63, No. 2, 1998, pp. 107-11.
[20] Yeap, Bu B., et al. “Reduced serum total osteocalcin is associated with metabolic syndrome in older men via
waist circumference, hyperglycemia, and triglyceride levels.” European Journal of Endocrinology Vol. 163, No.
2, 2010, pp. 265-72.
[21] Saleem, Umer, Thomas H. Mosley, and Iftikhar J. Kullo. “Serum osteocalcin is associated with measures of
insulin resistance, adipokine levels, and the presence of metabolic syndrome.” Arteriosclerosis, Thrombosis, and
Vascular Biology Vol. 30, No. 7, 2010, pp. 1474-78.
[22] Sarkar, P. D., and A. B. Choudhury. “Relationships between serum osteocalcin levels versus blood glucose, insuOgail
Yousif Dawod, et al. Int J Med Res Health Sci 2017, 6(10): 87-92
92
lin resistance and markers of systemic inflammation in central Indian type 2 diabetic patients.” European Review
for Medical and Pharmacological Sciences Vol. 17, No. 12, 2013, pp. 1631-35.
[23] Sanchez-Enriquez, Sergio, et al. “Serum levels of undercarboxylated osteocalcin are related to cardiovascular
risk factors in patients with type 2 diabetes mellitus and healthy subjects.” World Journal of Diabetes Vol. 8, No.
1, 2017, p. 11.
[24] Takashi, Yuichi, et al. “Undercarboxylated osteocalcin can predict insulin secretion ability in type 2 diabetes.”
Journal of Diabetes Investigation 2017.
[25] Ziegler, R. “Diabetes mellitus and bone metabolism.” Hormone and Metabolic Research. Supplement Series Vol.
26, 1992, pp. 90-94.
[26] Dhaliwal, R., et al. “Bone quality assessment in type 2 diabetes mellitus.” Osteoporosis International Vol. 25,
No. 7, 2014, pp. 1969-73.
[27] Verhaeghe, Johan, et al. “Bone mineral homeostasis in spontaneously diabetic BB rats. II. Impaired bone turnover
and decreased osteocalcin synthesis.” Endocrinology Vol. 124, No. 2, 1989, pp. 573-82.
[28] Gerdhem, Paul, et al. “Increased bone density and decreased bone turnover, but no evident alteration of fracture
susceptibility in elderly women with diabetes mellitus.” Osteoporosis International Vol. 16, No. 12, 2005, pp.
1506-12.
[29] Fulzele, Keertik, et al. “Insulin receptor signaling in osteoblasts regulates postnatal bone acquisition and body
composition.” Cell Vol. 142, No. 2, 2010, pp. 309-19.
[30] Bao, Yu-Qian, et al. “Relationship between serum osteocalcin and glycaemic variability in Type 2 diabetes.”
Clinical and Experimental Pharmacology and Physiology Vol. 38, No. 1, 2011, pp. 50-54.

Thank you for copying data from http://www.arastirmax.com